$4.30-0.20 (-4.44%)
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally.
Tilray Brands, Inc. in the Healthcare sector is trading at $4.30 with a market capitalization of $636M. Wall Street consensus targets $7.84 (8 analysts), implying a +82.4% move over the next 12 months. The stock is currently near its 52-week low of $3.67, remaining 34.8% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $281.71M↑ | $206.73M↓ | $217.51M↑ | $209.50M↓ | $224.53M |
| Gross Profit | $90.52M↑ | $54.95M↓ | $57.50M | $57.47M↓ | $67.63M |
| Operating Income | -$4.51M↑ | -$19.87M↑ | -$20.01M↓ | -$10.87M↑ | -$12.66M |
| Net Income | -$49.57M↓ | -$26.57M↑ | -$44.93M↓ | -$322,000↑ | -$1.27B |
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The compan...

In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $4.3, denoting a -4.44% move from the preceding trading day.

Don't expect a rebound anytime soon.

The Canadian cannabis companies are both seeing strong growth, but one is a better buy right now.

Tilray Brands, Inc. (TLRY) concluded the recent trading session at $4.5, signifying a -1.53% move from its prior day's close.
Key Takeaways; Cannabis Sector Aurora Cannabis Urged Shareholders to Reject Curaleaf’s Hostile Takeover Bid Tilray Expanded Global Cannabis Production as International Medical Demand Continues to Grow Key Takeaways; Psychedelic Sector Jupiter Neurosciences Raised $2 Million as the Company Advances its Parkinson’s Drug Program Optimi Health Secured Discretionary Equity Facility as Psychedelic Drug Business Expands SciSparc […]